Get started
Arvinas, Inc.Arvinas, Inc.Arvinas, Inc.

Arvinas, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

ARVN chart


Full chart

ARVN upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪508.91 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
—
Net income (FY)
‪−198.90 M‬ USD
Revenue (FY)
‪263.40 M‬ USD
Shares float
‪59.90 M‬
Beta (1Y)
1.57

Employees


Employees (FY)
430
Change (1Y)
−15 −3.37%
Revenue / Employee (1Y)
‪612.56 K‬ USD
Net income / Employee (1Y)
‪−462.56 K‬ USD

About Arvinas, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
John G. Houston
Website
arvinas.com
Headquarters
New Haven
Founded
2013
FIGI
BBG00LW7YK82
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ARVN news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as ARVN.

Frequently Asked Questions


The current price of ARVN is 7.56 USD — it has increased by 0.47% in the past 24 hours. Watch Arvinas, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Arvinas, Inc. stocks are traded under the ticker ARVN.
ARVN stock has risen by 10.64% compared to the previous week, the month change is a −13.04% fall, over the last year Arvinas, Inc. has showed a −77.94% decrease.
We've gathered analysts' opinions on Arvinas, Inc. future price: according to them, ARVN price has a max estimate of 110.00 USD and a min estimate of 10.00 USD. Watch ARVN chart and read a more detailed Arvinas, Inc. stock forecast: see what analysts think of Arvinas, Inc. and suggest that you do with its stocks.
ARVN reached its all-time high on Jul 29, 2021 with the price of 108.47 USD, and its all-time low was 5.94 USD and was reached on Apr 9, 2025. View more price dynamics on ARVN chart.
See other stocks reaching their highest and lowest prices.
ARVN stock is 3.48% volatile and has beta coefficient of 1.57. Track Arvinas, Inc. stock price on the chart and check out the list of the most volatile stocks — is Arvinas, Inc. there?
Today Arvinas, Inc. has the market capitalization of ‪521.29 M‬, it has decreased by −2.46% over the last week.
Yes, you can track Arvinas, Inc. financials in yearly and quarterly reports right on TradingView.
Arvinas, Inc. is going to release the next earnings report on May 6, 2025. Keep track of upcoming events with our Earnings Calendar.
ARVN earnings for the last quarter are −0.63 USD per share, whereas the estimation was −0.96 USD resulting in a 34.06% surprise. The estimated earnings for the next quarter are −0.96 USD per share. See more details about Arvinas, Inc. earnings.
Arvinas, Inc. revenue for the last quarter amounts to ‪59.20 M‬ USD, despite the estimated figure of ‪62.00 M‬ USD. In the next quarter, revenue is expected to reach ‪41.85 M‬ USD.
ARVN net income for the last quarter is ‪−45.10 M‬ USD, while the quarter before that showed ‪−35.20 M‬ USD of net income which accounts for −28.13% change. Track more Arvinas, Inc. financial stats to get the full picture.
No, ARVN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 16, 2025, the company has 430 employees. See our rating of the largest employees — is Arvinas, Inc. on this list?
Like other stocks, ARVN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Arvinas, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Arvinas, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Arvinas, Inc. stock shows the sell signal. See more of Arvinas, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.